Prion protein immunocytochemistry helps to establish the true incidence of prion diseases
Related Experiment Videos
P L Lantos1, I S McGill, I Janota
1Department of Neuropathology, Institute of Psychiatry, London, UK.
Abstract:
Creutzfeldt-Jakob disease (CJD) and Gerstmann-Strüssler-Scheinker disease (GSSD) are transmissible spongiform encephalopathies or prion diseases affecting man. It has been reported that prion diseases may occur without the histological hallmarks of spongiform encephalopathies: vacuolation of the cerebral grey matter, neuronal loss and astrocytosis. These cases without characteristic neuropathology may go undiagnosed and consequently the true incidence of transmissible dementias is likely to have been under-estimated. Immunocytochemistry using antibodies to prion protein gives positive staining of these cases, albeit the pattern of immunostaining differs from that seen in typical forms. Accumulation of prion protein is a molecular hallmark of prion diseases, and thus a reproducible, speedy and cost-efficient immunocytochemical screening of unusual dementias may help to establish the true incidence of prion diseases.
Insights
Creutzfeldt-Jakob disease (CJD) and Gerstmann-Strüssler-Scheinker disease (GSSD) are prion diseases. Prion diseases may lack typical signs, leading to underdiagnosis; immunocytochemistry aids in identifying these cases.
Area of Science:
- Neurology
- Pathology
- Molecular Biology
Background:
- Creutzfeldt-Jakob disease (CJD) and Gerstmann-Strüssler-Scheinker disease (GSSD) are human prion diseases.
- Prion diseases can manifest without classic neuropathological signs like spongiform changes, potentially leading to underestimation of their incidence.
- These atypical presentations pose diagnostic challenges, impacting the true understanding of transmissible dementias.
Purpose of the Study:
- To investigate the utility of immunocytochemistry in identifying prion diseases, particularly those lacking typical histological features.
- To highlight the role of prion protein accumulation as a molecular hallmark for diagnosing atypical prion disease cases.
- To propose immunocytochemistry as a screening tool for establishing the true incidence of prion diseases.
Main Methods:
- Utilized immunocytochemistry with prion protein antibodies to detect prion protein accumulation.
- Examined cases of suspected prion disease, including those without characteristic neuropathology.
- Compared immunostaining patterns in atypical cases with those in typical forms of CJD and GSSD.
Main Results:
- Immunocytochemistry detected prion protein in cases lacking typical spongiform encephalopathy hallmarks.
- The pattern of prion protein immunostaining differed between typical and atypical prion disease presentations.
- Positive prion protein staining confirms accumulation as a molecular hallmark, even in neuropathologically unusual cases.
Conclusions:
- Immunocytochemistry is effective in identifying prion diseases, even in the absence of classic histological findings.
- Prion protein accumulation is a reliable molecular marker for diagnosing prion diseases.
- A rapid, cost-efficient immunocytochemical screening approach can improve the diagnosis and incidence assessment of prion diseases, including CJD and GSSD.